Once-weekly versus twice-weekly carfilzomib in patients with newly diagnosed multiple myeloma: A pooled analysis of two phase i/ii studies

S. Bringhen, R. Mina, M.T. Petrucci, G. Gaidano, S. Ballanti, P. Musto, M. Offidani, S. Spada, G. Benevolo, E. Ponticelli, P. Galieni, M. Cavo, T.C. Di Toritto, F. Di Raimondo, V. Montefusco, A. Palumbo, M. Boccadoro, A. Larocca

Research output: Contribution to journalArticle

Cite this

Bringhen, S., Mina, R., Petrucci, M. T., Gaidano, G., Ballanti, S., Musto, P., Offidani, M., Spada, S., Benevolo, G., Ponticelli, E., Galieni, P., Cavo, M., Di Toritto, T. C., Di Raimondo, F., Montefusco, V., Palumbo, A., Boccadoro, M., & Larocca, A. (2019). Once-weekly versus twice-weekly carfilzomib in patients with newly diagnosed multiple myeloma: A pooled analysis of two phase i/ii studies. Haematologica, 104(8), 1640-1647. https://doi.org/10.3324/haematol.2018.208272